TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial.

Noureddin M, Alkhouri N, Lawitz EJ, Kowdley KV, Loomba R, Lee L, Jones C, Schlegel A, Marmon T, Anderson K, Li Y, Quirk E, Harrison SA

Open source

DOI
10.1038/s41591-025-03722-7
Published
2025 Jul
Container
Nature medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41591-025-03722-7,
  title = {TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial.},
  author = {Noureddin M and Alkhouri N and Lawitz EJ and Kowdley KV and Loomba R and Lee L and Jones C and Schlegel A and Marmon T and Anderson K and Li Y and Quirk E and Harrison SA},
  year = {2025},
  journal = {Nature medicine},
  doi = {10.1038/s41591-025-03722-7},
  url = {https://doi.org/10.1038/s41591-025-03722-7}
}

RIS

TY  - JOUR
TI  - TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial.
AU  - Noureddin M
AU  - Alkhouri N
AU  - Lawitz EJ
AU  - Kowdley KV
AU  - Loomba R
AU  - Lee L
AU  - Jones C
AU  - Schlegel A
AU  - Marmon T
AU  - Anderson K
AU  - Li Y
AU  - Quirk E
AU  - Harrison SA
PY  - 2025
JO  - Nature medicine
DO  - 10.1038/s41591-025-03722-7
UR  - https://doi.org/10.1038/s41591-025-03722-7
ER  - 

APA

M, N., N, A., EJ, L., KV, K., R, L., L, L., C, J., A, S., T, M., K, A., Y, L., E, Q., & SA, H. (2025). TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial.. Nature medicine. https://doi.org/10.1038/s41591-025-03722-7

Source records